{"product_id":"harrowinc-bcg-matrix","title":"Harrow Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Harrow BCG Matrix snapshot highlights where Harrow’s units sit across Stars, Cash Cows, Question Marks, and Dogs, offering a quick lens on growth potential and cash generation to guide portfolio moves. This preview scratches the surface—purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word + Excel package that helps you reallocate capital, prioritize product strategies, and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVEVYE Cyclosporine Solution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVEVYE Cyclosporine Solution has become a market leader in dry eye after its 2024 commercial launch, reaching 18% share of new premium prescriptions by Q4 2025 and growing at ~42% CAGR in prescriptions year-over-year.\u003c\/p\u003e\n\u003cp\u003eIts water-free formulation boosts ocular bioavailability, yielding a 25–35% higher tear-film retention in Phase IV real-world studies and supporting premium pricing at $175–$220 per monthly vial.\u003c\/p\u003e\n\u003cp\u003eThe brand requires heavy marketing spend—estimated $60–80M in 2025—to defend against legacy competitors, yet captures the dominant premium entry cohort and drives clinic formularies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIHEEZO Anesthetic Gel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIHEEZO Anesthetic Gel is a Star in Harrow’s BCG matrix, posting ~38% CAGR in U.S. ophthalmic sales and capturing ~22% share of clinic anesthetics by 2025; rapid onset (30–60s) and 90–120 minute duration drive high-volume cataract and refractive use.\u003c\/p\u003e\n\u003cp\u003eRevenue hit ~$145M in FY2025 while gross margin stayed ~68%; Harrow is spending ~$28M annually on sales force expansion to defend share versus lidocaine incumbents, keeping high reinvestment rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTRIESENCE Injectable Suspension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTRIESENCE Injectable Suspension is a star for Harrow after supply stabilization and capturing unmet demand for ocular steroid injections; it holds ~45–55% market share in the US retina injectable segment as of 2025 and benefits from a 6–8% annual rise in vitreoretinal surgeries (2021–2025 CAGR ~7%).\u003c\/p\u003e\n\u003cp\u003eThe brand consumes cash for manufacturing scale-up—capex ~ $18–25M through 2025—but drives strategic advantage in retina and surgical channels, supporting adjacent product launches and higher-margin hospital contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImprimisRx Surgical Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImprimisRx surgical compounded formulations lead office-based surgery solutions, with Harrow holding an estimated 55–60% market share in dropless cataract therapeutics as of Q4 2025 and year-over-year sales growth near 28%.\u003c\/p\u003e\n\u003cp\u003eSurgeon adoption of dropless models drives high demand; analyst surveys in 2025 show 42% of US cataract surgeons using dropless protocols, so Harrow needs sustained promotion to counter regional compounder entry.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: 55–60% (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eSales growth: ~28% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eSurgeon adoption: 42% using dropless (2025)\u003c\/li\u003e\n\u003cli\u003eRisk: regional compounders increasing promotional activity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIGAMOX and MOXEZA Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVIGAMOX and MOXEZA have been revitalized under Harrow, capturing an estimated 28% share of the US acute ophthalmic antibiotic market by 2025 and driving combined annual sales of about $72 million in FY2024.\u003c\/p\u003e\n\u003cp\u003eHarrow leveraged its distribution network to lift year-over-year revenue growth to 18% in 2024, while ongoing physician education programs sustained formulary preference and repeat prescribing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: ~28% (2025)\u003c\/li\u003e\n\u003cli\u003eCombined sales: ~$72M (FY2024)\u003c\/li\u003e\n\u003cli\u003eYoY revenue growth: 18% (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: physician education, distribution scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow Stars: Rapid Rx Gains — VEVYE, IHEEZO, TRIESENCE, ImprimisRx, VIGAMOX\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow Stars: VEVYE (18% new premium Rx share, 42% Rx CAGR to Q4 2025; price $175–220\/mo), IHEEZO (22% clinic anesthetics, ~$145M FY2025, 38% CAGR), TRIESENCE (45–55% retina injectables, capex $18–25M), ImprimisRx (55–60% dropless share, 28% YoY), VIGAMOX\/MOXEZA (28% acute antibiotics, $72M FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eShare (2025)\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eFY\/Spend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVEVYE\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e42% CAGR\u003c\/td\u003e\n\u003ctd\u003e$175–220\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIHEEZO\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e38% CAGR\u003c\/td\u003e\n\u003ctd\u003e$145M FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRIESENCE\u003c\/td\u003e\n\u003ctd\u003e45–55%\u003c\/td\u003e\n\u003ctd\u003e~7% market CAGR\u003c\/td\u003e\n\u003ctd\u003eCapex $18–25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprimisRx\u003c\/td\u003e\n\u003ctd\u003e55–60%\u003c\/td\u003e\n\u003ctd\u003e28% YoY\u003c\/td\u003e\n\u003ctd\u003e42% surgeon adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIGAMOX\/MOXEZA\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e18% YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e$72M FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Harrow’s products with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Harrow BCG Matrix mapping units to quadrants for instant strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMAXIDEX Ophthalmic Suspension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMAXIDEX Ophthalmic Suspension, a mature dexamethasone steroid, holds a stable ~35% share of Harrow’s anti-inflammatory eye-care portfolio and operates in a low-growth market (~2% CAGR 2023–2025), delivering steady, high-margin cash flow—reported gross margins near 68% in FY2024.\u003c\/p\u003e\n\u003cp\u003eIts established status cuts marketing spend to under 3% of product revenue, freeing roughly $4–6M annually for Harrow to reallocate toward R\u0026amp;D and pipeline programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eILEVRO and NEVANAC NSAIDs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eILEVRO and NEVANAC, established NSAID eye drops, are staples in post-op care with a loyal prescriber base, accounting for roughly $210M combined US annual Rx sales in 2024 (IQVIA). \u003c\/p\u003e\n\u003cp\u003eThough the NSAID category grew only ~2% CAGR 2020–24, these brands hold ~45% ophthalmic NSAID share and deliver steady cash flow, funding R\u0026amp;D and acquisitions of high-growth ophthalmic assets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Compounded Drops\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow’s legacy compounded steroid and antibiotic combos have hit market maturity: steady revenue with low capex and \u0026gt;40% gross margins reported in FY2024, driven by branded trust among long-term prescribers and a \u0026gt;10% annual churn reduction versus newer lines.\u003c\/p\u003e \n\u003cp\u003eThese cash cows fund interest on $210M net debt (2024) and bankroll new branded launches—about $25M allocated in 2025—while requiring minimal manufacturing upgrades and stable 3–5% annual volume declines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFLAREX and NATACYN Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFLAREX and NATACYN target niche inflammatory and antifungal eye conditions with limited competitors and steady demand; together they generated roughly $48.5M in 2024 net sales for Harrow, per company filings, acting as mature, low-growth cash cows that sustain margins above 35%.\u003c\/p\u003e\n\u003cp\u003eAs established brands with high regulatory and formulation barriers, they deliver protected revenue streams and near-zero incremental promo spend, contributing predictable operating cash flow used for R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales ~ $48.5M\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;35%\u003c\/li\u003e\n\u003cli\u003eLow promo spend, high operating cash conversion\u003c\/li\u003e\n\u003cli\u003eHigh barriers: regulatory, formulation, clinician familiarity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTOBRADEX ST Combination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTOBRADEX ST Combination remains a staple for corticosteroid-responsive inflammatory ocular conditions with secondary infections, holding an estimated 28% share of topical antibiotic-steroid prescriptions in the US ophthalmic market as of 2025 and delivering annual net sales around $145 million, per company reported figures.\u003c\/p\u003e\n\u003cp\u003eIts specialized suspension tech and decades-long trust among optometrists keep margins high; operating cash flow exceeds reinvestment needs, classifying it as a classic cash cow that funds corporate overhead and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~28% (2025)\u003c\/li\u003e\n\u003cli\u003eAnnual net sales ~$145M (2025)\u003c\/li\u003e\n\u003cli\u003eHigh gross margins; positive operating cash flow\u003c\/li\u003e\n\u003cli\u003eLong-standing optometrist brand loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow’s $451M cash cows: high margins, low promo, funding launches amid flat growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow cash cows (MAXIDEX, ILEVRO\/NEVANAC, FLAREX\/NATACYN, TOBRADEX ST) produced stable FY2024–25 net sales of ~$451M, gross margins 35–68%, low promo spend (\u0026lt;3% revenue), funding $25M 2025 launches and servicing $210M net debt while showing ~2% market CAGR and 3–5% annual volume declines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 Net Sales\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003cth\u003ePromo %Rev\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAXIDEX\u003c\/td\u003e\n\u003ctd\u003e$~XXM (35% portfolio share)\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eILEVRO\/NEVANAC\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003ctd\u003e~40–50%\u003c\/td\u003e\n\u003ctd\u003e~3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFLAREX\/NATACYN\u003c\/td\u003e\n\u003ctd\u003e$48.5M\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;35%\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTOBRADEX ST\u003c\/td\u003e\n\u003ctd\u003e$145M\u003c\/td\u003e\n\u003ctd\u003e~45–60%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eHarrow BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Harrow BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report tailored for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748215468409,"sku":"harrowinc-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harrowinc-bcg-matrix.png?v=1772206164","url":"https:\/\/matrixbcg.com\/products\/harrowinc-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}